Alyeska Investment Group
NRIX icon

Alyeska Investment Group’s Nurix Therapeutics NRIX Stock Holding History

Alyeska Investment Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Buy
+138,122
New +$2.35M 0.01% 539
2022
Q2 		– Sell
-120,750
Closed -$1.69M – 636
2022
Q1 		$1.69M Buy
120,750
+5,750
+5% +$102K 0.02% 450
2021
Q4 		$3.33M Hold
115,000
– – 0.04% 360
2021
Q3 		$3.44M Buy
+115,000
New +$3.55M 0.04% 401

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group's NRIX Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 138,122 shares worth $3.35M. The stake represents 0.01% of the portfolio and ranks #539 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in NRIX as recently as Q1 2022.

Alyeska Investment Group first reported a position in NRIX in Q3 2021 and has held it in 4 quarters since. The position peaked at $3.44M in Q3 2021. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Alyeska Investment Group held 138,122 shares of Nurix Therapeutics worth $3.35M as of Q2 2026.
  • Nurix Therapeutics was a new Alyeska Investment Group position in Q2 2026.
  • Nurix Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #539 holding.
  • Alyeska Investment Group first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Alyeska Investment Group's Nurix Therapeutics position peaked at $3.44M in Q3 2021.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.